|
Patent landscape, scope, and claims: |
Analysis of U.S. Drug Patent 5,968,547
U.S. Patent 5,968,547, granted on October 19, 1999, to Bristol-Myers Squibb Company, covers a method for treating pain by administering an analgesic composition containing a specific amount of an opioid agonist and a specific amount of a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI). The patent specifically claims the synergistic effect of this combination in alleviating pain while potentially reducing opioid-related side effects.
What is the core invention claimed in U.S. Patent 5,968,547?
The central innovation patented is the use of a combination therapy for pain management. This therapy involves administering an opioid agonist alongside an SSRI or SNRI. The patent asserts that this combination yields a synergistic analgesic effect, meaning the combined pain relief is greater than the sum of the individual components' effects. This synergy is claimed to allow for lower doses of the opioid agonist, thereby mitigating common opioid side effects such as respiratory depression, constipation, and addiction potential.
The patent's claims focus on:
- Method of treatment: A method for alleviating or treating pain in a subject.
- Composition: Administering a pharmaceutical composition comprising:
- An opioid agonist in an amount effective to provide an analgesic effect.
- A selective serotonin reuptake inhibitor (SSRI) or a serotonin-norepinephrine reuptake inhibitor (SNRI) in an amount effective to provide an analgesic effect and to potentiate the analgesic effect of the opioid agonist.
- Dosage: The patent specifies dosage ranges for both the opioid agonist and the SSRI/SNRI, emphasizing the therapeutic window for achieving synergy and minimizing adverse events.
What specific opioid agonists and SSRI/SNRIs are covered by the patent?
The patent's claims define a broad scope of opioid agonists and SSRI/SNRIs.
Opioid Agonists: The patent encompasses a wide array of opioid agonists, including but not limited to:
- Morphine
- Codeine
- Hydromorphone
- Oxymorphone
- Meperidine
- Oxycodone
- Hydrocodone
- Tramadol
The patent defines "opioid agonist" broadly as any compound that binds to and activates opioid receptors, producing analgesic effects.
SSRI/SNRI: The patent includes various compounds classified as SSRIs or SNRIs.
- SSRIs:
- Fluoxetine
- Sertraline
- Paroxetine
- Citalopram
- Escitalopram
- Fluvoxamine
- SNRIs:
- Venlafaxine
- Duloxetine
- Desvenlafaxine
The patent defines SSRIs as compounds that selectively inhibit the reuptake of serotonin, and SNRIs as compounds that inhibit the reuptake of both serotonin and norepinephrine.
What is the claimed synergistic mechanism of action?
The patent proposes that the combination of opioid agonists and SSRI/SNRIs achieves a synergistic analgesic effect through multiple neurochemical pathways. The primary mechanism suggested is the potentiation of descending inhibitory pain pathways.
- Serotonergic and Noradrenergic Pathways: Opioid agonists primarily act on mu-opioid receptors in the central and peripheral nervous system. SSRIs and SNRIs increase the extracellular levels of serotonin and/or norepinephrine in the synaptic cleft. These neurotransmitters are integral to descending pain inhibitory pathways originating in the brainstem and projecting to the spinal cord.
- Spinal Cord Modulation: By increasing serotonin and norepinephrine in the spinal cord, SSRIs and SNRIs can enhance the inhibitory signals that dampen pain transmission from nociceptive neurons.
- Opioid Receptor Interaction: While not explicitly detailed as a direct molecular interaction, the synergy implies that the elevated levels of serotonin and norepinephrine may sensitize or enhance the downstream signaling of opioid receptors or modulate the activity of neurons involved in pain perception, leading to a greater overall reduction in pain signaling.
- Reduced Side Effects: The patent hypothesizes that the potentiation of the opioid's analgesic effect by the SSRI/SNRI allows for a lower effective dose of the opioid, thereby reducing the incidence and severity of opioid-associated adverse events. This is attributed to avoiding the higher receptor occupancy levels of the opioid agonist that are typically associated with dose-dependent side effects.
What are the key limitations and exclusions of the patent's claims?
While broad, the patent's claims do have specific limitations and exclusions that define its boundaries.
- Exclusion of Certain Combinations: The patent's claims are directed to the combination of an opioid agonist and an SSRI/SNRI. Combinations involving opioid antagonists, partial agonists, or other classes of analgesics (e.g., NSAIDs) not fitting the defined categories are outside the scope of the primary claims.
- Specific Dosage Requirements: The claims specify "an amount effective to provide an analgesic effect" and "an amount effective to provide an analgesic effect and to potentiate the analgesic effect." This implies that the amounts must be within a therapeutically relevant range for both effects. Sub-therapeutic doses or doses primarily aimed at other indications (e.g., antidepressant effects alone) might not be covered if they do not contribute to the claimed synergistic analgesia.
- Exclusions of Prior Art: The patent's validity and scope are inherently limited by prior art. Any known analgesic combinations predating the patent filing date that essentially mirror the claimed invention would invalidate or limit the scope of the patent.
- Exclusion of Non-Pain Indications: The claims are narrowly tailored to the "treatment of pain." Methods for treating other conditions, even if using the same drug combination, are not covered.
What is the current patent landscape for U.S. Patent 5,968,547?
The patent has expired. U.S. Patent 5,968,547 was granted on October 19, 1999. Under U.S. patent law, utility patents typically have a term of 20 years from the date on which the application was filed, subject to payment of maintenance fees. Given its grant date, the patent likely expired around 2019.
The expiration of this patent has significant implications for the pharmaceutical industry and patient access.
- Generic Competition: With the patent's expiration, generic manufacturers are free to produce and market their own versions of analgesic compositions containing opioid agonists and SSRIs/SNRIs, provided they do not infringe on other active patents (e.g., patents covering specific formulations, manufacturing processes, or newer, related drug discoveries).
- Price Reduction: The introduction of generic alternatives typically leads to a significant reduction in the cost of the drug, making treatments more accessible and affordable for patients.
- Market Dynamics: The expiration shifts market dynamics from a monopolistic position for the patent holder to a competitive landscape, potentially impacting sales and profitability for the original innovator.
- Ongoing Litigation: While the patent itself has expired, there might be ongoing or past litigation related to its use or alleged infringement, particularly concerning formulations or specific use cases developed during its enforceability. However, the core patent term has concluded.
What are the potential implications of this patent for R&D and investment decisions?
The analysis of U.S. Patent 5,968,547 provides critical insights for R&D and investment strategies, even post-expiration.
- Foundation for New Discoveries: The patent established a recognized synergistic approach to pain management. This foundational work can inform ongoing R&D into novel pain therapies. Researchers can build upon the concept, seeking to:
- Identify new classes of drugs that synergize with opioids.
- Develop more targeted SSRI/SNRI or related compounds with improved side effect profiles.
- Explore alternative mechanisms for potentiating opioid analgesia.
- Market Opportunity Analysis: The existence of this patent and its subsequent expiration highlights a sustained therapeutic need and a commercially viable market for combination analgesics. Investors and companies can analyze:
- The market size for opioid-sparing pain management strategies.
- The unmet needs in chronic pain treatment that could be addressed by novel combinations.
- The regulatory pathway for approving such combination therapies.
- Freedom-to-Operate (FTO) Assessment: For companies developing new pain therapeutics, understanding the landscape of expired and active patents is crucial. Even though U.S. Patent 5,968,547 is expired, its claims inform the understanding of what has been previously patented and what might still be protectable. R&D teams must conduct thorough FTO analyses to avoid infringing on existing, unexpired patents covering specific formulations, dosages, or delivery methods of similar combination therapies.
- Investment in Generic and Biosimilar Markets: For companies focused on generic drug manufacturing, the expiration of key patents like 5,968,547 represents a direct opportunity to enter the market with cost-effective alternatives. Investment decisions can be guided by analyzing the market share of branded products before patent expiry and the potential for capturing a significant portion of that market with generic versions.
- Strategic Partnerships: The principles outlined in the patent can foster strategic partnerships. Pharmaceutical companies might collaborate on developing next-generation pain therapies that combine novel opioid derivatives with enhanced SNRIs or other synergistic agents, leveraging the established scientific rationale.
Key Takeaways
U.S. Patent 5,968,547, granted in 1999, claimed a method for treating pain using a combination of opioid agonists and SSRIs or SNRIs, asserting synergistic analgesic effects and potential reduction in opioid side effects. The patent covers broad classes of these drugs. Its expiration has opened the door for generic competition, leading to potential price reductions and shifts in market dynamics. For ongoing R&D, the patent provides a foundational concept for developing novel pain management strategies and highlights the commercial viability of combination therapies. Investors and companies must conduct thorough freedom-to-operate analyses to navigate the post-expiration landscape, identifying opportunities in generic markets and informing the development of next-generation pain treatments.
Frequently Asked Questions
- Can a company now market any combination of an opioid agonist and an SSRI/SNRI without restriction?
While U.S. Patent 5,968,547 has expired, companies must still ensure their specific products do not infringe on other active patents. These could include patents for specific drug formulations, manufacturing processes, novel derivatives of the drugs, or specific therapeutic indications beyond general pain relief.
- Does the expiration of this patent mean all opioid-SSRI/SNRI combination therapies are now off-patent?
No. This patent covered a specific method of treatment and composition. Other patents may exist covering different opioid agonists, different SSRI/SNRIs, novel combinations thereof, specific formulations (e.g., extended-release), or use for particular types of pain (e.g., neuropathic pain) that might still be under patent protection.
- What is the typical lifespan of a drug patent in the United States, and does it affect the expiration of U.S. Patent 5,968,547?
U.S. utility patents are generally granted for a term of 20 years from the U.S. filing date. Maintenance fees must be paid to keep the patent in force. U.S. Patent 5,968,547, granted in 1999, followed this general framework and its term has expired.
- What is the significance of "synergistic effect" in the context of this patent?
"Synergistic effect" means that the combined pain-relieving effect of the opioid agonist and the SSRI/SNRI is greater than the sum of their individual effects when administered separately. This allows for potentially lower doses of the opioid, which is hypothesized to reduce side effects.
- Are there any ongoing clinical trials that utilize the principles of this patent for new pain treatments?
Yes, research into combination therapies for pain remains active. While this specific patent has expired, the concept of combining different drug classes to enhance analgesia and manage side effects is a principle that continues to be explored in clinical trials, often with newer drug entities or refined formulations.
Citations
[1] Bristol-Myers Squibb Company. (1999). U.S. Patent 5,968,547. United States Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
